Naratriptan Orifarm (Naratriptan)

• Naratriptan is a Triptan medication used to treat migraine‑related conditions.
• Migraine attacks (without aura): reduces headache intensity and associated symptoms when taken at the onset of an attack.
• Migraine attacks (with aura): alleviates headache after the aura phase and provides rapid relief.
• Acute episodic migraine: offers prompt relief for single migraine episodes when administered early.

• Naratriptan binds selectively to 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve endings. Activation of these receptors produces vasoconstriction of dilated intracranial arteries and inhibits the release of pro‑inflammatory neuropeptides, thereby interrupting the migraine cascade and reducing pain transmission.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Dizziness: transient feeling of light‑headedness.
• Fatigue: unusual tiredness or weakness.
• Dry mouth: reduced salivation.
• Tingling sensations: paresthesia in extremities.
• Drowsiness: increased sleepiness.

Serious or Rare Side Effects

• Chest pain or tightness: possible cardiac ischemia.
• Severe hypertension: sudden rise in blood pressure.
• Serotonin syndrome: agitation, hyperthermia, muscle rigidity.
• Allergic reactions: rash, swelling, or anaphylaxis.
• Abdominal pain: intense or persistent discomfort.
• Vision changes: blurred vision or visual disturbances.

• Before prescribing Naratriptan, clinicians should consider several safety factors.
• Cardiovascular assessment: evaluate history of coronary artery disease before use.
• Serotonergic drug use: avoid combined use with other serotonergic agents due to serotonin syndrome risk.
• Pregnancy: use only if potential benefit justifies potential risk to the fetus.
• Elderly patients: start at the lowest effective dose and monitor tolerance.
• Renal impairment: dose adjustment may be required based on renal function.
• Store at room temperature: keep in the original pack, protect from moisture and light.

Naratriptan may interact with several medication classes.

Major Interactions (Avoid)

• Ergot alkaloids: combined use can cause severe vasospasm.
• MAO inhibitors: increased serotonergic effects may lead to serotonin syndrome.
• SSRIs, SNRIs, or other serotonergic agents: heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may increase plasma concentrations of Naratriptan.
• CYP3A4 inhibitors (e.g., ketoconazole): can raise Naratriptan exposure.
• CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effectiveness.